Twelve Week Data to be Presented at the Annual Meeting of the European Association for the Study of the Liver LOUISVILLE, Colo. – April 23, 2009 – Twelve-week Phase 2 clinical trial data show that patients treated with GI-5005, GlobeImmune’s … Continue reading
GlobeImmune’s Hepatitis C Therapeutic Vaccine, GI-5005, Improves EVR Rates to 94 percent in Phase 2 Clinical Trial
April 24, 2009